| |
Total
(N = 540) |
Completersb
(n = 406) |
Non-completersc
(n = 134) |
Difference** |
| |
n |
% |
n |
% |
n |
% |
χ2 (df), p |
| Gender |
|
|
|
|
|
|
9.53 (1), .002 |
Female |
210 |
38.9 |
173 |
42.6 |
37 |
27.6 |
|
Male |
330 |
61.1 |
233 |
57.4 |
97 |
72.4 |
|
| |
|
|
|
|
|
|
|
| Primary Substance Use History |
|
|
|
|
|
|
5.20 (5), .393 |
None |
65 |
12.0 |
51 |
12.6 |
14 |
10.4 |
|
Alcohol |
183 |
33.9 |
129 |
31.8 |
54 |
40.3 |
|
Opiates* |
64 |
11.9 |
51 |
12.6 |
13 |
9.7 |
|
Cocaine |
140 |
25.9 |
105 |
25.9 |
35 |
26.1 |
|
Marijuana |
63 |
11.7 |
52 |
12.8 |
11 |
8.2 |
|
Methamphetamine and related drugs |
25 |
4.6 |
18 |
4.4 |
7 |
5.2 |
|
| |
|
|
|
|
|
|
|
| Primary Mental Health Diagnosisa |
|
|
|
|
|
|
3.36 (3), .339 |
None |
125 |
23.1 |
88 |
21.7 |
37 |
27.6 |
|
Mood disorder |
301 |
55.7 |
227 |
55.9 |
74 |
55.2 |
|
Anxiety disorder |
77 |
14.3 |
63 |
15.5 |
14 |
10.4 |
|
Psychotic disorder |
37 |
6.9 |
28 |
6.9 |
9 |
6.7 |
|
| |
|
|
|
|
|
|
|
| Pharmacotherapyd |
|
|
|
|
|
|
1.45 (1), .228 |
Monotherapy |
141 |
26.9 |
103 |
25.6 |
38 |
31.1 |
|
Combination therapy |
383 |
73.1 |
300 |
74.4 |
84 |
68.9 |
|
| |
|
|
|
|
|
|
|
| |
Mean |
SD |
Mean |
SD |
Mean |
SD |
t (df), p |
| Age of participant (years) |
48.1 |
11.0 |
48.3 |
11.0 |
47.4 |
10.9 |
.833 (536), .405 |
| |
|
|
|
|
|
|
|
| Age at smoking initiation |
14.8 |
4.9 |
14.9 |
5.0 |
14.5 |
4.7 |
.739 (532), .460 |
| |
|
|
|
|
|
|
|
| Importance of quitting |
9.0 |
1.3 |
9.0 |
1.3 |
9.0 |
1.4 |
.286 (520), .775 |
| |
|
|
|
|
|
|
|
| Confidence in quitting |
7.3 |
2.2 |
7.3 |
2.3 |
7.4 |
2.1 |
.330 (515), .741 |
| |
|
|
|
|
|
|
|
| Cigarettes smoked per day |
21.0 |
10.3 |
21.1 |
10.6 |
20.6 |
9.5 |
.469 (538), .639 |
| |
|
|
|
|
|
|
|
| FTNDf at baseline |
6.1 |
2.1 |
6.1 |
2.1 |
6.1 |
2.0 |
.325 (532), .746 |
| |
|
|
|
|
|
|
|
| CO level at baseline |
20.7 |
12.5 |
20.6 |
12.1 |
21.2 |
13.5 |
.482 (520), .630 |
a. The ‘mood disorder’ category includes primarily individuals with depression and bipolar disorder. The ‘anxiety disorder’ category includes individuals primarily with
generalized anxiety disorder, posttraumatic stress disorder, and panic disorders. The ‘psychotic disorder’ category includes individuals with a primary past history of schizophrenia,
schizoaffective disorder, psychotic disorder.
b. Program completers are individuals who had at least 6 contacts with the Tobacco Dependence Clinic program. The typical program involves 8 weeks (8 contact points) of
a closed group therapy session. Individuals could miss no more than two weeks (two contacts) to still have meaningful participation in the program. Of program completers,
8.4% (n =17) had 6 or 7 contacts with the program.
c. Program non-completers are individuals who had engaged in the program for more than two weeks, but had a total of less than 6 contact points (i.e., less than 6 weeks
in the program).
d. Pharmacotherapy represents the form of treatment (i.e., monotherapy vs. combination therapy) in the first month of treatment.
e. mean differences between completers and non-completers is expected as, by definition, non-completers did not have more than 6 weeks (6 contacts) with the program.
f. FTND = Fagerstrom Test for Nicotine Dependence. This is a six-item questionnaire of nicotine dependence, scored on a scale of ‘0’ (low) and ‘10’ (high).
* opiates (i.e., oxycontin, codeine, methadone, heroin)
** differences between groups was based on chi-square analysis for categorical variables and independent sample t-tests for continuous variables. |
